Hrh Medic Drug Cards

Front 1

Epinephrine
(Dosage) Cardiac Arrest

Back 1

Dosage Adult: Cardiac Arrest: • Adult: 1 mg ( 1 : 10,000 solution) IV, IO; may repeat every 3 to 5 minutes. Symptomatic Bradycardia: • Adult: 1 mcg/ min ( 1 : 10,000 solution) as a continuous IV infusion; usual dosage range: 2 to 10 mcg/ min IV; titrate to effect.

Front 2

0.9% Normal Saline
(Medication)

Back 2

Medication: Isotonic Solution

Front 3

0.9% Normal Saline
(Indications)

Back 3

Indications: Heat related problems ( heat exhaustion, heat stroke), Fresh water Drowning, Hypovolemia, Diabetic Ketoacidosis.

Front 4

0.9% Normal Saline
(Dosage)

Back 4

Dossage: Depends on pt condition and situation, heat related rapid infusion, after that 100 ml/hr

Front 5

0.9% Normal Saline
(Adverse Reactions)

Back 5

Adverse Reactions: Rare in therapeutic Dosage, Thirst

Front 6

PROPOFOL
(Trade name)

Back 6

Medication -DIPRIVAN

Front 7

Propofol
(Classification)

Back 7

Classification Anesthetic

Front 8

Proprfol
(Adverse Effects)

Back 8

Adverse Effects Apnea, cardiac arrhythmias, asystole, hypotension, hypertension, pain at injection site.

Front 9

Propofol
(Dosage)

Back 9

Dosage
Adult patients: 25 to 75 mcg/ kg/ min IV, IO. Pediatric: 125 to 300 mcg/ kg/ min IV, IO.

Front 10

0.9% Normal Saline
(Contraindications)

Back 10

Contraindications-CHF pt because of circulatory overload.

Front 11

0.9% Normal Saline
(MOA)

Back 11

MOA-fluid and sodium replacement

Front 12

FENTANYL CITRATE
(Trade Name)

Back 12

( SUBLIMAZE)

Front 13

FENTANYL CITRATE
(Classification)

Back 13

Classification- Narcotic analgesic; Schedule C- II

Front 14

FENTANYL CITRATE
(MOA)

Back 14

(MOA)-Binds to opiate receptors, producing analgesia and euphoria.

Front 15

FENTANYL CITRATE
(Indications)

Back 15

Indications Pain

Front 16

FENTANYL CITRATE
(Adverse Effects)

Back 16

Adverse Effects-Respiratory depression, apnea, hypotension, nausea/ vomiting, dizziness, sedation, euphoria, sinus bradycardia, sinus tachycardia, palpitations, hypertension, diaphoresis, syncope, pain at injection site.

Front 17

FENTANYL CITRATE
(Contraindications)

Back 17

Contraindications-Known sensitivity. Use with caution in traumatic brain injury, respiratory depression

Front 18

MIDAZOLAM
(Classification)

Back 18

Classification-Benzodiazepine

Front 19

MIDAZOLAM
(Indications)

Back 19

Indications-Sedation, anxiety, skeletal muscle relaxation.

Front 20

MIDAZOLAM
(Adverse Effects)

Back 20

laryngospasm, bronchospasm, dyspnea, respiratory depression and/ or arrest, drowsiness, amnesia, altered mental status, bradycardia, tachycardia, PVC, and n/v

Front 21

MIDAZOLAM
(Contraindications)

Back 21

hypersensitivity, narrow angle glaucoma, shock, depressed vital signs, alcoholic coma

Front 22

MIDAZOLAM
(Dosage)

Back 22

1 to 10 mg, peds 0.05 to 0.1 mg/kg

Front 23

LIDOCAINE
(Classification)

Back 23

Classification- Antiarrhythmic

Front 24

LIDOCAINE
(Indications)

Back 24

May be necessary for patient's with head injuries or stroke, prior to RSI/ RSA

Front 25

LIDOCAINE
(Adverse Effects)

Back 25

Anxiety, drowsiness, dizziness, confusion, N/V, convulsions, widening of QRS complexes

Front 26

SUCCINYLCHOLINE
(Classification)

Back 26

Classification: Neuromuscular blocker, depolarizing

Front 27

SUCCINYLCHOLINE
(Action)

Back 27

Action-Competes with the acetylcholine receptor of the motor end plate on the muscle cell, resulting in muscle paralysis.

Front 28

SUCCINYLCHOLINE
(Indications)

Back 28

Indications- To induce neuromuscular blockade for the facilitation of ET intubation.

Front 29

SUCCINYLCHOLINE
(Adverse Effects)

Back 29

Adverse Effects- Anaphylactoid reactions, respiratory depression, apnea, bronchospasm, cardiac arrhythmias, malignant hyperthermia, hypertension, hypotension, muscle fasciculation, postprocedure muscle pain, hypersalivation, rash.

Front 30

SUCCINYLCHOLINE
(Contraindications)

Back 30

Contraindications- Malignant hyperthermia, burns, trauma. Use with caution in children, cardiac disease, hepatic disease, renal disease, peptic ulcer disease, cholinesterase- inhibitor toxicity, pseudocholinesterase deficiency, digitalis toxicity, glaucoma, hyperkalemia, hypothermia, rhabdomyolysis, myasthenia gravis.

Front 31

SUCCINYLCHOLINE
(Dosage)

Back 31

Dosage:
Adult: • IV: 0.6 mg/ kg IV, IO ( range 0.3- 1.1 mg/ kg). • IM: 3 to 4 mg/ kg ( max dose: 150 mg).

• Pediatric: • IV: • Adolescents and older children: 1 mg/ kg IV, IO. • Small children and infants: 2 mg/ kg IV, IO. • IM: 3 to 4 mg/ kg ( max dose: 150 mg

Front 32

ETOMIDATE
(Classification)

Back 32

Classification- Hypnotic, anesthesia induction agent

Front 33

ETOMIDATE
(Indications)

Back 33

Induction agent for RSI/RSA

Front 34

ETOMIDATE
(Adverse Effects)

Back 34

myoclonic skeletal muscle movement, apnea, hyperventilation or hypoventilation, larynogspasm, hypertension or hypotension, tachycardia or bradycardia, N/V

Front 35

ETOMIDATE
(Contraindications)

Back 35

Contraindications- Known sensitivity.

Front 36

ETOMIDATE
(Dosage)

Back 36

0.1 to 0.3 mg/ kg/ IV

Front 37

ROCURONIUM
(Classification)

Back 37

Neuromuscular blocker, nondepolarizing

Front 38

ROCURONIUM
(Action)

Back 38

Action- Antagonizes acetylcholine at the motor end plate, producing skeletal muscle paralysis.

Front 39

ROCURONIUM
(Indications)

Back 39

To induce neuromuscular blockade for the facilitation of ET intubation.

Front 40

ROCURONIUM
(Adverse Effects)

Back 40

Adverse Effects: Muscle paralysis, apnea, dyspnea, respiratory depression, sinus tachycardia, urticaria.

Front 41

ROCURONIUM
(Contraindications)

Back 41

Contraindications: Known sensitivity to bromides. Use with caution in heart disease, liver disease.

Front 42

Ipratropium
(Indications)

Back 42

Indications: Asthma, bronchospasm associated with COPD.

Front 43

Ipratropium
(Dosage)

Back 43

Nebulization:
*Adult: 0.5 mg every 6 to 8 hours.

*Pediatric: 5 to 14 years: 0.25 to 0.5 mg every 20 minutes for 3 doses as needed.

Front 44

Ipratropium
(Contraindications)

Back 44

Contraindications: Closed- angle glaucoma, bladder neck obstruction, prostatic hypertrophy, known sensitivity including peanuts or soybeans and atropine or atropine derivatives.

Front 45

Ipratropium
(Adverse Effects)

Back 45

Adverse Effects: Paradoxical acute bronchospasm, cough, throat irritation, headache, dizziness, dry mouth, palpitations.

Front 46

Lactated Ringers
(Classification)

Back 46

Classification- Isotonic Crystolloid

Front 47

Lactated Ringers
(Indications)

Back 47

hypovolemic shock

Front 48

Lactated Ringers
(Dosage)

Back 48

Dosage: depends on Pt's condition and situation. when systolic <90mmHg> "wide open" until 100mm when 100mL/hr *Peds 20mL/kg repeated as based on hemodynamic response

Front 49

Lactated Ringers
(Adverse reaction)

Back 49

Adverse Reactions: Rare

Front 50

Lactated Ringers
(Contraindications)

Back 50

Contraindications: congestive heart failure; renal Failure

Front 51

Lactated Ringers
(MOA)

Back 51

MOA: Replace water and electrolytes

Front 52

Epinephrine
(Classification)

Back 52

Classification: Adrenergic agent, inotropic (EPIPEN)

Front 53

Epinephrine
(Indications)

Back 53

Indications: Bronchospasm, allergic and anaphylactic reactions, restoration of cardiac activity in cardiac arrest.

Front 54

Epinephrine
(Contraindications)

Back 54

Contraindications: Arrhythmias other than VF, asystole, PEA; cardiovascular disease; hypertension; cerebrovascular disease; shock secondary to causes other than anaphylactic shock; closed- angle glaucoma; diabetes; pregnant women in active labor; known sensitivity to epinephrine or sulfites.

Front 55

Epinephrine
(Adverse Effects)

Back 55

Adverse Effects: Anxiety, headache, cardiac arrhythmias, hypertension, nervousness, tremors, chest pain, nausea/ vomiting.

Front 56

Epinephrine
(MOA)

Back 56

MOA: Binds strongly with both alpha and beta receptors, producing increased blood pressure, increased heart rate, bronchodilation.

Front 57

Albuterol
(Classification)

Back 57

Classification: Bronchodilator, beta agonist (PROVENTIL, VENTOLIN)

Front 58

Albuterol
(Indications)

Back 58

Indications: Asthma, bronchitis with bronchospasm, and COPD.

Front 59

Albuterol
(Dosage)

Back 59

Dosage
Adult Nebulizer: 2.5 to 5 mg every 20 minutes for a maximum of three doses.

Peds• Older than 12 years: The dose for a continuous nebulization is 0.5 mg/ kg/ hr. • Younger than 12 years: 0.15 mg/ kg every 20 minutes for a maximum of three doses

Front 60

Albuterol
(Contraindications)

Back 60

Contraindications: Angioedema, sensitivity to albuterol or levalbuterol. Use with caution in lactating patients, cardiovascular disorders, cardiac arrhythmias.

Front 61

Albuterol
(Adverse Effects)

Back 61

Adverse effects: Hyperglycemia, hypokalemia, palpita-tions, sinus tachycardia, anxiety, tremor, nausea/ vomiting, throat irritation, dry mouth, hypertension, dyspepsia, insomnia, headache, epistaxis, paradoxical bronchospasm.

Front 62

Albuterol
(MOA)

Back 62

MOA: Binds and stimulates beta2 receptors, resulting in relaxation of bronchial smooth muscle.

Front 63

Atropine
(Classification)

Back 63

Classification: Anticholinergic ( antimuscarinic)

Front 64

Atropine
(Indications)

Back 64

Indications: Symptomatic bradycardia, asystole or PEA, nerve agent exposure, organophosphate poisoning.

Front 65

Atropine
(Dosage)

Back 65

Dosage: Symptomatic Bradycardia:
* Adult: 0.5 mg IV, IO every 3 to 5 minutes to a maximum dose of 3 mg.
* Pediatric: 0.02 mg/ kg ( minimum 0.1 mg/ dose; maximum 0.5 mg/ dose) IV, IO, to a total dose of 1 mg

Front 66

Atropine
(Contraindications)

Back 66

Contraindications: Acute MI; myasthenia gravis; GI obstruction; closed- angle glaucoma; known sensitivity to atropine.

Front 67

Atropine
(Adverse Effects)

Back 67

Adverse Effects: Decreased secretions resulting in dry mouth and hot skin temperature, intense facial fl ushing, blurred vision or dilation of the pupils with subsequent photophobia, tachycardia, restlessness.

Front 68

Atropine
(MOA)

Back 68

MOA: Competes reversibly with acetylcholine at the site of the muscarinic receptor. Receptors affected, in order from the most sensitive to the least sensitive, include salivary, bronchial, sweat glands, eye, heart, and GI tract.

Front 69

Levalbuterol
(Classification)

Back 69

XOPENEX

Front 70

Levalbuterol
(Indications)

Back 70

Acute bronchospasm or bronchospasm prophylaxis in patient with asthma.

Front 71

Levalbuterol
(Dosage)

Back 71

Nebulizer: •
*Adult: Usually, 0.63 mg 3 times/ day. For acute exacerbations, 1.25 to 2.5 mg every 20 minutes for 3 doses.
*Peds For acute exacerbations, 0.075 mg/ kg ( 1.25 mg minimum) every 20 minutes for 3 doses

Front 72

Levalbuterol
(Contraindications)

Back 72

Contraindications: Angioedema, sensitivity to albuterol or leval-buterol. Use with caution in lactating patients, cardiovascular disorders, cardiac arrhythmias.

Front 73

Levalbuterol
(Adverse Effects)

Back 73

Adverse Effects-Side Effects: Hyperglycemia, hypokalemia, palpitations, sinus tachycardia, anxiety, tremor, nausea/ vomiting, throat irritation, hypertension, dyspepsia, insomnia, headache.

Front 74

Levalbuterol
(MOA)

Back 74

MOA: Stimulates beta2 receptors, resulting in relaxation of the smooth muscle in the lungs, uterus, and vasculature that supply skeletal muscle.

Front 75

Terbutaline
(Classification)

Back 75

Classificatoin- Adrenergic agonist

Front 76

Terbutaline
(Indications)

Back 76

bronchial asthma and reversible bronchospasm associated with COPD

Front 77

Terbutaline
(Dosage)

Back 77

• Adult: 0.25 mg

Front 78

Terbutaline
(Contraindications)

Back 78

hypersensitivity, use with caution in hypertension, and CAD

Front 79

Terbutaline
(Adverse Effects)

Back 79

palpitations, anxiety, dizziness, HA, nervousness, tremors, hypertension, dysrhythmias, chest pain, N/V

Front 80

Terbutaline
(MOA)

Back 80

MOA: Stimulates the beta2 receptor, producing relaxation of bronchial smooth muscle and bronchodilation.

Front 81

Aminophylline
(Classifications)

Back 81

Classification-Bronchodilator

Front 82

Aminophylline
(Indications)

Back 82

bronchial asthma, reversible bronchospasm associated with COPD

Front 83

Aminophylline
(Dosage)

Back 83

250 to 500 mg, not to exceed 17 mg/kg

Front 84

Aminophylline
(Contraindications)

Back 84

hypersensitivity, uncontrolled cardiac dysrhythmias

Front 85

Aminophylline
(Adverse Effects)

Back 85

tachycardia, dysrhythmias, palpitations, chest pain, nervousness, headache, seizures, n/v

Front 86

Aminophylline
(MOA)

Back 86

MOA: Xanthine bronchodilator

Front 87

Solumedrol
(Classification)

Back 87

Classification -Corticosteroid

Front 88

Solumedrol
(Indications)

Back 88

Indications Anaphylaxis, asthma, COPD

Front 89

Solumedrol
(Dosage)

Back 89

10-250 mg (common prehospital dosages: 125 and 250 mgs)

Front 90

Solumedrol
(Contraindications)

Back 90

None in severe anaphylaxis, use with caution in diabetics and immuno compromised.

Front 91

Solumedrol
(Adverse Effects)

Back 91

Increased blood sugar, chf, fluid retention, vertigo, HA, Nausea, malaise, abdominal distention, increased ICP

Front 92

Solumedrol
(MOA)

Back 92

MOA: Reduces inflammation by multiple mechanisms.
(Glucocorticoid (Corticosteroid) and anti-inflammatory)

Front 93

D5W (Classifications)

Back 93

Classifications-Hypotonic Dextrose Solution

Front 94

D5W (Indications)

Back 94

Indications: IV access for emergency drugs; for dilution of concentrated drugs for IV infusion

Front 95

D5W (Dosage)

Back 95

Dosage: usually administered through a minidrip 60 drops/mL. (TKO)

Front 96

D5W (Adverse reactions)

Back 96

Adverse reactions: Rare

Front 97

D5W (Contraindications)

Back 97

Contraindications: not as fluid replacement for hypovolemic states; head injury and stroke

Front 98

D5W (MOA)

Back 98

MOA: glucose nutrient solution

Front 99

D5LR (Medication)

Back 99

Medication: Hypertonic sugar and electrolyte solution

Front 100

D5LR (Indications)

Back 100

Indications: hypovolemic shock; hemorrhagic shock; certain cases of acidosis

Front 101

D5LR (Dosage)

Back 101

Dosage: depends on Pt's condition and situation

Front 102

D5LR (Contraindications)

Back 102

Contraindications: decreased renal and Cardiovascular function head injury and stroke

Front 103

D5LR (MOA)

Back 103

MOA: electrolyte and sugar replacement

Front 104

Oxygen (Classification)

Back 104

Classification- Gas, Element

Front 105

Oxygen (Indications)

Back 105

Indications: hypoxia, ischemic chest pain, respiratory distress, suspected carbon monoxide poising, traumatic injuries and stroke

Front 106

Oxygen (Dosage)

Back 106

Dosage: cardiac arrest & critical 100%, other administer only enough to correct hypoxia

Front 107

Oxygen (Adverse Reactions)

Back 107

Adverse Reactions: Drying mucous membrane, high concentrations can cause decreased (LOC). and respiratory depression in pt with chronic carbon dioxide retention or chronic lung disease.

Front 108

Oxygen (Contraindications)

Back 108

Contraindications: known paraquat poising( fertilizer poising)

Front 109

Oxygen (MOA)

Back 109

MOA: necessary for cellular Metabolism.

Front 110

Propofol (Action)

Back 110

Action- Produces rapid and brief state of general anesthesia

Front 111

Propofol (Indications)

Back 111

Indidications- Anesthesia induction.

Front 112

SUCCINYLCHOLINE (Trade Name)

Back 112

ANECTINE

Front 113

MIDAZOLAM (Trade Name)

Back 113

VERSED

Front 114

LIDOCAINE (Trade Name)

Back 114

XYLOCAINE

Front 115

Solumedrol (Trade Name)

Back 115

METHYLPREDNISOLONE SODIUM SUCCINATE

Front 116

ETOMIDATE (Trade Name)

Back 116

AMIDATE

Front 117

Trebutaline (Trade Name)

Back 117

Brethine

Front 118

(Epinephrine)
Asthma Attacks and Certain Allergic Reactions: Adult dosage

Back 118

• Adult: 0.3 to 0.5 mg ( 1 : 1000 solution) IM or Sub- Q; may repeat every 10 to 15 minutes ( max dose: 1 mg).

Front 119

(Epinephrine)
Anaphylactic Shock

Back 119

• Adult: 0.1 mg ( 1 : 10,000 solution) IV slowly over 5 minutes, or IV infusion of 1 to 4 mcg/ min, titrated to effect.

Front 120

Albuteral (Trade Name)

Back 120

PROVENTIL, VENTOLIN

Front 121

ROCURONIUM (Trade Name)

Back 121

ZEMURON

Front 122

Ipratropium (Trade Name)

Back 122

ATROVENT

Front 123

ETOMIDATE (Trade Name)

Back 123

AMIDATE

Front 124

Racemic Epinephrine (Name)

Back 124

Vaponefrin

Front 125

Racemic Epinephrine (Indications)

Back 125

Indicated to treat laryngotracheobronchiitis (croup)

Front 126

Racemic Epinephrine (Contraindications)

Back 126

Caution should be used in epiglottis

Front 127

Racemic Epinephrine (Dosage)

Back 127

0.25 to 0.75 ml diluted with 2 ml (2.25%)

Front 128

Racemic Epinephrine (Side effects)

Back 128

Rebounding, tachycardia, nervousness

Front 129

Racemic Epinephrine (MOA)

Back 129

Stimulation of both alpha and beta adrenergic receptors resulting in some bronchial dilation and reduction in subglottic edema.

Front 130

Lidocaine (Dosage)

Back 130

1mg/kg

Front 131

Lidocaine (Contraindications)

Back 131

Known allergies, High degree AV blks, Bradycardia with PVC

Front 132

Lidocaine (MOA)

Back 132

Antidysrhythmic that supresses ventricular ectopy, reduces velocity of impulses through conductive system

Front 133

Decadron (Trade Name)

Back 133

Dexamthasone

Front 134

Decadron (Indications)

Back 134

Anaphylaxis, Asthma, COPD

Front 135

Decadron (Contraindications)

Back 135

none in emergency settings

Front 136

Decadron (Dosage)

Back 136

4-10 mg, peds 0.2-0.5 mg/kg

Front 137

Decadron (Side effects)

Back 137

GI bleeding, prolonged wound healing

Front 138

Decadron (MOA)

Back 138

Steroid/ anti-inflammatory